

Figure 2. Transplantation Procedures for Tissue-Engineered Autologous Epithelial-Cell Sheets.

Preoperatively, the entire corneal surface was covered by conjunctival tissue with neovascularization (Panel A). In Panel B, conjunctival tissue over the cornea is surgically removed to reexpose transparent corneal stroma. Then, the sheet of tissue-engineered epithelial cells is harvested from a temperature-responsive culture insert with the use of a doughnut-shaped supporter ([black-and-white squares] Panel C) and placed on the stromal bed (Panel D). The sheet adheres to corneal stroma in a few minutes without sutures, and the supporter is removed (Panel E), leaving the cell sheet on the stroma (Panel F). A video clip can be viewed in the Supplementary Appendix, available with the full text of this article at [www.nejm.org](http://www.nejm.org).


amination with fluorescein sodium staining showed complete reepithelialization of the corneal surface in all four eyes, revealing the tight junction-mediated barrier function. Corneal transparency was restored without any defects of the corneal epithelium. In all eyes, stromal vascularization gradually recurred in the peripheral cornea but not in the central zone. This vascularization was unlike subepithelial vascularization accompanied by conjunctival ingrowth, since it was localized to the deeper stroma and did not show the abnormally high fluorescein permeability characteristic of conjunctival epithelium.

During a mean follow-up period of 14 months, corneal transparency was maintained (Fig. 3 and Table 2). Maximally improved visual acuity was obtained 6, 2, 10, and 8 weeks after transplantation for Patients 1 through 4, respectively, and became stable thereafter. The length of time until visual acuity improved seemed to correspond to the length of time until the corneal stroma became less opaque. No complications were observed.

## DISCUSSION

Our study shows that tissue-engineered cell sheets from autologous oral mucosal epithelium may serve as effective substitutes for allografts of limbal tissue in the reconstruction of the corneal and limbal surfaces. Four patients (four eyes) were consecutively treated with this approach, and corneal transparency was restored and postoperative visual acuity improved remarkably (Table 2). During the follow-up period, all corneal surfaces remained transparent, and there were no serious complications.

We developed this strategy on the basis of several observations from cell biology and medicine. First, *in vivo* oral mucosal epithelium expresses keratin 3, which is also expressed by the corneal epithelium but not by the epidermis.<sup>1,27</sup> Second, the excision of a small piece of oral mucosal tissue from the patient is straightforward, and the resulting wound heals within several days without incident or scarring. Third, transplantation of autologous



buccal mucosal grafts directly onto ocular surfaces was previously reported in human patients<sup>28</sup> for the purposes of treating corneal ulcers, corneal perforations, and lid abnormalities (e.g., marginal entropion and trichiasis); these grafts are not useful for improving vision, since they contain opaque subepithelial fibrous tissue. In contrast, the transparency of carrier-free sheets of tissue-engineered epithelial cells fabricated from oral mucosal epithelial cells is similar to the transparency of corneal epithelial-cell sheets originating from limbal stem cells.<sup>23</sup>

Reconstruction with autologous oral mucosal epithelial cells offers substantial clinical advantages over allogeneic transplantation for treating severe diseases such as the Stevens–Johnson syndrome and ocular pemphigoid. It averts the risks of allogeneic immunorejection and immunosuppression. Severe tear-film and lid abnormalities often associated with these diseases continue to be a challenge, since immunologically driven inflammation of the ocular surface persists chronically in these patients.

Although decisive epithelial stem-cell markers that could provide evidence of the presence of these stem cells in grafted cell sheets have not yet been established,<sup>29</sup> results from colony-forming assays for oral mucosal epithelium show that excised oral tissue contains epithelial stem cells or at least progenitor cells. Since ocular surfaces that have been grafted with cell sheets retain their transparency for more than one year, and because the life spans of transient amplifying cells (cells committed to epithelial differentiation) are believed to be less than one year,<sup>30</sup> we conclude that progenitor cells with the potential to differentiate into new corneal epithelial phenotype are present in autografts of cell sheets.

Conjunctival epithelial cells invade the cornea after allogeneic transplantation because of the gradual depletion of allogeneic corneal epithelial cells due to epithelial rejection or stem-cell depletion.<sup>31–33</sup> It is unknown whether this also applies to autologous transplants. In the four eyes we studied, limited stromal vascularization occurred within a few months after transplantation of the cell sheet and reached a stable state within six months, with no appreciable growth thereafter. This stromal vascularization was observed only beneath cell sheets on peripheral corneas and should be distinguished from the subepithelial neovascularization accompanied by conjunctival ingrowth that results from the stem-cell loss associated with allografts, which occurs several months after transplantation. This finding suggests that grafted oral mucosal epithelial cells remained on the ocular surface.

It is possible that the reduction in host immunologic reactions associated with the grafting of autologous cells may minimize epithelial rejection, but further study is needed. The limited stromal neovascularization that we observed is probably caused by angiogenic factors secreted from tissue-engineered epithelial-cell sheets fabricated from oral mucosal epithelial cells originally located in

Table 2. Surgical Outcome in Four Patients Who Received Transplants of Tissue-Engineered Autologous Oral Mucosal-Cell Sheets.

Patient No.	Best Corrected Visual Acuity in Damaged Eye		Corneal Opacity (Grade)*			Complication	Months of Follow-up
	Preoperative†	Postoperative	Preoperative	1 Month	At Last		
				after Surgery	Observation		
1	Counting fingers	20/100	3	2	1	None	15
2	20/2000	20/25	3	1	1	None	14
3	Hand motion	20/300	3	1	1	None	14
4	20/2000	20/50	3	1	1	None	13

\* The extent of corneal opacity was graded by three masked observers on the basis of the slit-lamp examination with a previously described system<sup>26</sup> and modifications for ocular-surface diseases. Grade 0 indicates clear or trace haze, grade 1 mild opacity, grade 2 moderately dense opacity partially obscuring details of the iris, and grade 3 severely dense opacity obscuring details of the intraocular structure. Grading is based on the opacity observed in all corneal layers, including epithelium, stroma, and endothelium.

† The visual acuity of patients who could not read a visual-acuity chart at a distance of 0.5 m was assessed by asking whether they could see the number of fingers held up by the examiner. If they could not, visual acuity was assessed by the patient's ability to see hand movement by the examiner.

vivo on the substantia propria, which is rich in vessels. However, the production of antiangiogenic factors such as thrombospondin by keratocytes<sup>34</sup> may limit vascularization to peripheral areas.

We observed that the transplanted cell sheets became more transparent and achieved smoother, integrated surfaces on the corneal stroma, further resembling normal corneal epithelium; a plateau was reached one to three months after transplantation. Originally, oral mucosal epithelium, located on substantia propria, is morphologically distinct from corneal epithelium in that it is much thicker and multilayered and has an irregular surface (Fig. 1C). The use of temperature-responsive harvesting allows the grafted carrier-free oral mucosal epithelial cells to interact immediately and directly with patients' corneal stromal keratocytes without interference from cell carriers such as fibrin gel and amniotic membranes.

Our transplantable epithelial-cell sheets used the common 3T3 feeder-layer method originally developed for the production of autologous epidermal-cell grafts<sup>35</sup> and used in the culture of other

epithelial cells from various tissue sources, including the limbus.<sup>16</sup> This method has been clinically applied since the 1980s for the treatment of various skin conditions, including burns and giant nevi, although the Food and Drug Administration classifies these grafts as xenografts.

In summary, we have shown that sheets of tissue-engineered epithelial cells fabricated *ex vivo* from autologous oral mucosal epithelium are effective for reconstructing the ocular surface and restoring vision in patients with bilateral total stem-cell deficiencies. Long-term follow-up and experience with a large series of patients are needed to assess further the benefits and risks of this method, which offers the potential to treat severe ocular diseases that are resistant to standard approaches.

Supported by Grants-in-Aid for Scientific Research (15390530, 16200036, and 16300161), the High-Tech Research Center Program, and the Center of Excellence Program for the 21st Century from the Ministry of Education, Culture, Sports, Science, and Technology in Japan and by the Core Research for Evolution Science and Technology from the Japan Science and Technology Agency.

We are indebted to Professor David Grainger, Colorado State University, and Mr. Joseph Yang, Tokyo Women's Medical University, for their technical review.

## REFERENCES

- Schermer A, Galvin S, Sun TT. Differentiation-related expression of a major 64K corneal keratin *in vivo* and in culture suggests limbal location of corneal epithelial stem cells. *J Cell Biol* 1986;103:49-62.
- Cotsarelis G, Cheng SZ, Dong G, Sun TT, Lavker RM. Existence of slow-cycling limbal epithelial basal cells that can be preferentially stimulated to proliferate: implications on epithelial stem cells. *Cell* 1989;57:201-9.
- Thoft RA, Friend J. The X, Y, Z hypothesis of corneal epithelial maintenance. *Invest Ophthalmol Vis Sci* 1983;24:1442-3.
- Buck RC. Measurement of centripetal migration of normal corneal epithelial cells in the mouse. *Invest Ophthalmol Vis Sci* 1985; 26:1296-9.
- Tseng SC. Concept and application of limbal stem cells. *Eye* 1989;3:141-57.
- Nishida K. Tissue engineering of the cornea. *Cornea* 2003;22:Suppl 7:S28-S34.

7. Kenyon KR, Tseng SC. Limbal autograft transplantation for ocular surface disorders. *Ophthalmology* 1989;96:709-22.
8. Chen JJ, Tseng SC. Corneal epithelial wound healing in partial limbal deficiency. *Invest Ophthalmol Vis Sci* 1990;31:1301-14.
9. Dua HS, Azuara-Blanco A. Autologous limbal transplantation in patients with unilateral corneal stem cell deficiency. *Br J Ophthalmol* 2000;84:273-8.
10. Tsubota K, Satake Y, Kaido M, et al. Treatment of severe ocular-surface disorders with corneal epithelial stem-cell transplantation. *N Engl J Med* 1999;340:1697-703.
11. Samson CM, Nduaguba C, Baltatzis S, Foster CS. Limbal stem cell transplantation in chronic inflammatory eye disease. *Ophthalmology* 2002;109:862-8.
12. Ilari L, Daya SM. Long-term outcomes of keratolimbal allograft for the treatment of severe ocular surface disorders. *Ophthalmology* 2002;109:1278-84.
13. Shimazaki J, Shimamura S, Fujishima H, Tsubota K. Association of preoperative tear function with surgical outcome in severe Stevens-Johnson syndrome. *Ophthalmology* 2000;107:1518-23.
14. Schwab IR, Reyes M, Isseroff RR. Successful transplantation of bioengineered tissue replacements in patients with ocular surface disease. *Cornea* 2000;19:421-6.
15. Tsai RJ, Li LM, Chen JK. Reconstruction of damaged corneas by transplantation of autologous limbal epithelial cells. *N Engl J Med* 2000;343:86-93.
16. Rama P, Bonini S, Lambiase A, et al. Autologous fibrin-cultured limbal stem cells permanently restore the corneal surface of patients with total limbal stem cell deficiency. *Transplantation* 2001;72:1478-85.
17. Nakamura T, Endo K, Cooper LJ, et al. The successful culture and autologous transplantation of rabbit oral mucosal epithelial cells on amniotic membrane. *Invest Ophthalmol Vis Sci* 2003;44:106-16.
18. Kinoshita S, Nakamura T. Development of cultivated mucosal epithelial sheet transplantation for ocular surface reconstruction. *Artif Organs* 2004;28:22-7.
19. Yamato M, Okano T. Cell sheet engineering. *Mater Today* 2004;May:42-7.
20. Kawasaki S, Nishida K, Sotozono C, Quantock AJ, Kinoshita S. Conjunctival inflammation in the chronic phase of Stevens-Johnson syndrome. *Br J Ophthalmol* 2000;84:1191-3.
21. Foster CS, Fong LP, Azar D, Kenyon KR. Episodic conjunctival inflammation after Stevens-Johnson syndrome. *Ophthalmology* 1988;95:453-62.
22. Hirose M, Kwon OH, Yamato M, Kikuchi A, Okano T. Creation of designed shape cell sheets that are noninvasively harvested and moved onto another surface. *Biomacromolecules* 2000;1:377-81.
23. Nishida K, Yamato M, Hayashida Y, et al. Functional bioengineered corneal epithelial sheet grafts from corneal stem cells expanded ex vivo on a temperature-responsive cell culture surface. *Transplantation* 2004;77:379-85.
24. Jones PH, Watt FM. Separation of human epidermal stem cells from transit amplifying cells on the basis of differences in integrin function and expression. *Cell* 1993;73:713-24.
25. Pellegrini G, Dellambra E, Golisano O, et al. p63 Identifies keratinocyte stem cells. *Proc Natl Acad Sci U S A* 2001;98:3156-61.
26. Fantes FE, Hanna K, Waring GO III, Pouliquen Y, Thompson KP, Salvodelli M. Wound healing after excimer laser keratomileusis (photorefractive keratectomy) in monkeys. *Arch Ophthalmol* 1990;108:665-75.
27. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. *Cell* 1982;31:11-24.
28. Shore JW, Foster CS, Westfall CT, Rubin PA. Results of buccal mucosal grafting for patients with medically controlled ocular cicatricial pemphigoid. *Ophthalmology* 1992;99:383-95.
29. Dua HS, Joseph A, Shanmuganathan VA, Jones RE. Stem cell differentiation and the effects of deficiency. *Eye* 2003;17:877-85.
30. Kinoshita S, Friend J, Thoft RA. Sex chromatin of donor corneal epithelium in rabbits. *Invest Ophthalmol Vis Sci* 1981;21:434-41.
31. Holland EJ, Schwartz GS. Epithelial stem-cell transplantation for severe ocular-surface disease. *N Engl J Med* 1999;340:1752-3.
32. Shimazaki J, Kaido M, Shinozaki N, et al. Evidence of long-term survival of donor-derived cells after limbal allograft transplantation. *Invest Ophthalmol Vis Sci* 1999;40:1664-8.
33. Williams KA, Brereton HM, Aggarwal R, et al. Use of DNA polymorphisms and the polymerase chain reaction to examine the survival of a human limbal stem cell allograft. *Am J Ophthalmol* 1995;120:342-50.
34. Hiscott P, Sorokin L, Nagy ZZ, Schlotzer-Schrehardt U, Naumann GO. Keratocytes produce thrombospondin 1: evidence for cell phenotype-associated synthesis. *Exp Cell Res* 1996;226:140-6.
35. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. *Cell* 1975;6:331-43.

Copyright © 2004 Massachusetts Medical Society.

#### POSTING PRESENTATIONS AT MEDICAL MEETINGS ON THE INTERNET

Posting an audio recording of an oral presentation at a medical meeting on the Internet, with selected slides from the presentation, will not be considered prior publication. This will allow students and physicians who are unable to attend the meeting to hear the presentation and view the slides. If there are any questions about this policy, authors should feel free to call the *Journal's* Editorial Offices.